title: [Role of surgery in the treatment of pulmonary aspergillosis].
abstract: BACKGROUND
  This article reviews the different forms of pulmonary disease caused by aspergillus and discusses the possible surgical treatments. The most well known is the classic aspergilloma which develops as a fungal ball in the centre of a pre-existing pulmonary cavity.
  
  
  BACKGROUND
  One can distinguish simple (few symptoms, thin walled cavity without immediate complications) and complex forms (patient generally unwell, thick cavity, complications). In the complex form, surgical intervention must be considered as a last resort. In the simple form, surgery is relatively benign and prevents disease progression. Pleural aspergillosis can occur, usually following the surgical removal of a cavity either in the short or medium term. Given the loss of lung parenchyma thoracoplasty is often the only option.
  
  
  OBJECTIVE
  Two different scenarios occur in acute invasive aspergillosis where surgery may be indicated: firstly, surgery can be considered in the event of haemoptysis related to vascular erosion; secondly, resection of mycotic sequestrations before intensification or resumption of therapy may prevent a relapse. Semi-invasive aspergillosis usually occurs in territories of post-radiation fibrosis: after a phase of invasion equivalent to a lobar pneumonia, a secondary cavity appears containing a small fungal ball. Thoracoplasty is often the only surgical option. Ulcerating tracheobronchial aspergillosis has been observed following (cardio-) pulmonary transplant and this may progress to a characteristic invasive aspergillosis.
  
  
  CONCLUSIONS
  Finally, rare observations of parietal aspergillosis could be treated by surgical resection and associated with systemic antifungal therapy. Optimum management of these patients requires a multidisciplinary approach.
authors.affiliation: Service de Chirurgie Thoracique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. Gilbert.Massard@chru-strasbourg.fr
authors.forename: G
authors.initials: G
authors.lastname: Massard
mesh_terms: D000208:Acute Disease; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology / Q000601:surgery*; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*; D003131:Combined Modality Therapy; D004198:Disease Susceptibility; D004322:Drainage; D006469:Hemoptysis / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008172:Lung Diseases, Fungal / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology / Q000601:surgery*; D010995:Pleural Diseases / Q000188:drug therapy / Q000382:microbiology / Q000601:surgery; D011013:Pneumonectomy / Q000379:methods*; D011183:Postoperative Complications / Q000188:drug therapy / Q000382:microbiology / Q000601:surgery; D011859:Radiography; D012008:Recurrence; D035441:Thoracic Wall; D014397:Tuberculosis, Pulmonary / Q000150:complications; D014456:Ulcer / Q000209:etiology
chemical_list: D000935:Antifungal Agents